Journal · Updated 2026-08-11
Semaglutide 2.4 mg: The Full Dose — the 14.9% Arm, the SELECT Dose, the Destination
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
2.4 mg weekly is semaglutide's studied home: 14.9% average body-weight loss at 68 weeks in STEP-1, the dose behind SELECT's 20% cardiovascular-event reduction, and the arm that met tirzepatide in SURMOUNT-5's head-to-head (13.7% versus 20.2% at 72 weeks, open-label, Lilly-funded — the fair-context version our comparison keeps attached). Maintenance at full dose is standard practice per the withdrawal data; the ladder above now includes a 7.2 mg tier (priced at $399 on NovoCare's card) for the escalation conversation's new frontier; and every channel sells this rung — $349 pens, $129–$139 compounded floor, the $25 insured path — making 2.4 the dose where the price pages and the evidence pages finally describe the same product.
Full dose, fully framed
Three contexts complete the picture. Against expectations: 14.9% was the average — distributions ran wide, a third of STEP-1 participants exceeded 20% while others responded modestly, and an individual's settled result is a fact to work with, not a grade. Against tirzepatide: the head-to-head gap is real and so are the reasons semaglutide keeps its half of the market — the SELECT cardiovascular indication tirzepatide doesn't yet hold, the deeper long-term safety record, the oral option, and price floors thirty-to-forty dollars lower at every compounded tier. Above 2.4: the 7.2 mg tier extends the ladder for inadequate responders — a prescriber conversation with newer evidence and a $50 brand-price step — while the non-dose levers (protein, training, sleep, the plateau checklist) remain the first response to any stall at full dose. Mechanics: at 2.5 mg/mL, 2.4 mg = 0.96 mL (96 units — functionally a full syringe, where higher-concentration vials commonly take over and the re-read rule peaks in importance); ~5-day window; and the procedure hold as at every dose.
Questions people ask
What results does semaglutide 2.4 mg actually produce?
STEP-1: 14.9% average loss at 68 weeks, with wide variation (about a third exceeded 20%). SELECT added a 20% cardiovascular-event reduction in overweight patients with heart disease. Head-to-head, SURMOUNT-5 showed tirzepatide ahead (20.2% vs 13.7%) — open-label and Lilly-funded, context included.
Do I stay on 2.4 mg forever?
Maintenance at full dose is standard — the withdrawal trials show most weight returning when treatment stops, so the dose that achieved the result commonly keeps it. Down-titration experiments are prescriber-guided; the new 7.2 mg tier exists for the opposite conversation.
How many units is 2.4 mg of compounded semaglutide?
At 2.5 mg/mL: 0.96 mL = 96 units — essentially a full U-100 syringe, which is why higher concentrations (5 mg/mL: 48 units) are common at this dose and why the vial's mg/mL line gets re-read on every single refill.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.